Rhabdomyosarcoma natural history, complications and prognosis

Rhabdomyosarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Rhabdomyosarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Rhabdomyosarcoma natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Rhabdomyosarcoma natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Rhabdomyosarcoma natural history, complications and prognosis
CDC on Rhabdomyosarcoma natural history, complications and prognosis
Rhabdomyosarcoma natural history, complications and prognosis in the news
Blogs on Rhabdomyosarcoma natural history, complications and prognosis
Directions to Hospitals Treating Rhabdomyosarcoma
Risk calculators and risk factors for Rhabdomyosarcoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Prognosis

• Rhabdomyosarcoma is associated with a 5 year survival rate of 72%.
• The presence of metastasis is associated with a particularly poor prognosis among patients with rhabdomyosarcoma. The 5 year event free survival rate is less than 30%.
• Embryonal type rhabdomyosarcoma is associated with most favorable prognosis.
• Prognosis varies with location of tumor- orbital and genitourinary tract rhabdomyosarcomas have the most favorable prognosis.